Omnicyte is a pre-clinical biotech company having developed a novel Immuno-Oncology platform technology that selectively activates the cancer immune system to target, infiltrate and destroy specific tumor types, without activating unrelated immune elements, which can cause immunotoxic side effects. The firm's technology can be engineered to safely attack numerous different tumor types with the first two indications being ovarian cancer and small cell lung cancer. OmniCyteâs patented technology is based on the human oncogene hRgr. hRgr has been shown to be active in an identifiable subset of Acute Lymphoblastic Leukemia patients. While hRgr is active in other malignancies, this orphan indication was chosen as the initial indication to pursue because of numerous financial and strategic incentives. The firm is currently working through an LLS grant to combine a therapeutic with molecular diagnostic to work in a fashion analogous to Gleevec and Herceptin. therapeutic targeting a subset of children with the deadly disease Acute Lymphoblastic Leukemia
